Related Experiment Video

Updated: Apr 6, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K

Optimal Concurrent Chemoradiotherapy Regimen in Non-Small-Cell Lung Cancer: Prospective, Randomized Data Still

Alfredo Addeo1, Charles Comins2

  • 1Bristol Cancer Centre, Bristol, United Kingdom alfredo.addeo@uhBristol.nhs.uk.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|July 29, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

492

Related Experiment Videos

Last Updated: Apr 6, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

11.1K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

15.2K
Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer
11:17

Thoracoscopic Extended Right Middle Plus Lower Sleeve Lobectomy for Non-Small-Cell Lung Cancer

Published on: February 27, 2026

492

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K

Articles linked to this work by shared authors, journal, and citation graph.

PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypes.

Cancer treatment reviews·2026

Decision-Making in Intrathecal Therapy for Leptomeningeal Disease.

Oncology·2026

Definitive Radiotherapy With or Without Chemotherapy After Planned Neoadjuvant Chemoimmunotherapy in Stages II to III NSCLC: An International Multicenter Retrospective Study.

JTO clinical and research reports·2026

Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer·2026

Real-world outcomes of stage III NSCLCs managed by surgery or definitive radiation therapy in the era of immunotherapy.

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·2026

Efficacy of Immune Checkpoint Inhibitors and Oncoviruses in Solid Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Pathologic Complete Response (pCR) Rate and Predictors of Response to Taxane, Trastuzumab, and Pertuzumab in HER2‑Positive Breast Cancer: Secondary Analyses of EA1181/CompassHER2 pCR.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.3.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Living Guideline, Version 2026.1.2.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Laser Interstitial Thermal Therapy for Brain Tumors: A Prospective Multicenter Analysis of Patients From the LAANTERN Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

Clinical management of adverse events in patients with advanced HER2+ metastatic breast cancer treated with tucatinib, trastuzumab, and capecitabine.

The oncologist·2026

Treatment Initiation of Definitive Radiotherapy in Patients With Locally Advanced Head and Neck Cancer.

Cancer control : journal of the Moffitt Cancer Center·2026

[Retracted] Restoration of the tumor‑suppressor function to mutant p53 by Ganoderma lucidum polysaccharides in colorectal cancer cells.

Oncology reports·2026

Octreotide as Adjunctive Therapy for Catecholamine-Secreting Pheochromocytoma and Paraganglioma.

The Journal of clinical endocrinology and metabolism·2026

Zanubrutinib versus fludarabine, cyclophosphamide and rituximab in fit, treatment-naïve patients with chronic lymphocytic leukemia: a matching-adjusted indirect comparison.

Journal of comparative effectiveness research·2026

Prognosis of Extramedullary Disease in Chinese Newly Diagnosed Multiple Myeloma Patients Treated With Novel Agents-Based Induction Therapy.

Cancer medicine·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us